Apellis Pharmaceuticals Inc (NASDAQ:APLS) has a beta value of 0.88 and has seen 2.82 million shares traded in the recent trading session. The company, currently valued at $3.00B, closed the recent trade at $24.60 per share which meant it lost -$3.96 on the day or -13.87% during that session. The APLS stock price is -200.0% off its 52-week high price of $73.80 and -6.83% below the 52-week low of $26.28. If we look at the company’s 10-day average daily trading volume, we find that it stood at 3.03 million shares traded. The 3-month trading volume is 2.21 million shares.
The consensus among analysts is that Apellis Pharmaceuticals Inc (APLS) is Buy stock at the moment, with a recommendation rating of 1.59. 0 analysts rate the stock as a Sell, while 1 rate it as Overweight. 2 out of 14 have rated it as a Hold, with 11 advising it as a Buy. 0 have rated the stock as Underweight.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Apellis Pharmaceuticals Inc (NASDAQ:APLS) trade information
Sporting -13.87% in the red today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the APLS stock price touched $24.60 or saw a rise of 18.35%. Year-to-date, Apellis Pharmaceuticals Inc shares have moved -58.90%, while the 5-day performance has seen it change -10.25%. Over the past 30 days, the shares of Apellis Pharmaceuticals Inc (NASDAQ:APLS) have changed -10.38%. Short interest in the company has seen 21.09 million shares shorted with days to cover at 6.81.
Wall Street analysts have a consensus price target for the stock at $78.5, which means that the shares’ value could jump 68.66% from the levels at last check today.. The projected low price target is $39.0 while the price target rests at a high of $113.0. In that case, then, we find that the latest price level in today’s session is -359.35% off the targeted high while a plunge would see the stock gain -58.54% from the levels at last check today..
Apellis Pharmaceuticals Inc (APLS) estimates and forecasts
Figures show that Apellis Pharmaceuticals Inc shares have outperformed across the wider relevant industry. The company’s shares have lost -43.96% over the past 6 months, with this year growth rate of 68.54%, compared to 17.30% for the industry.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -13.70% over the past 5 years. Earnings growth for 2024 is a modest 70.32% while over the next 5 years, the company’s earnings are expected to increase by 33.30%.
APLS Dividends
Apellis Pharmaceuticals Inc is expected to release its next earnings report on 2024-Nov-05 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Apellis Pharmaceuticals Inc (NASDAQ:APLS)’s Major holders
Insiders own 14.28% of the company shares, while shares held by institutions stand at 98.25% with a share float percentage of 114.62%. Investors are also buoyed by the number of investors in a company, with Apellis Pharmaceuticals Inc having a total of 382.0 institutions that hold shares in the company. The top two institutional holders are WELLINGTON MANAGEMENT GROUP LLP with over 16.39 million shares worth more than $628.67 million. As of 2024-06-30, WELLINGTON MANAGEMENT GROUP LLP held 13.3288% of shares outstanding.
The other major institutional holder is ECOR1 CAPITAL, LLC, with the holding of over 11.61 million shares as of 2024-06-30. The firm’s total holdings are worth over $445.26 million and represent 9.3681% of shares outstanding.
